このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effects of Rhodiola Rosea Supplementation on Anaerobic Performance and Blood Lactate in Trained Men

2026年11月9日 更新者:Yucel Makaraci、Karamanoğlu Mehmetbey University

Effects of Short-term Rhodiola Rosea Supplementation on Anaerobic Performance and Serial Post-exercise Blood Lactate Responses in Trained Men: A Randomized, Double-blind, Placebo-controlled Crossover Trial

This study aimed to investigate the effects of short-term Rhodiola rosea supplementation on anaerobic exercise performance and blood lactate responses during post-exercise recovery in trained male athletes.

The study used a randomized, double-blind, placebo-controlled crossover design involving 23 trained men. Each participant completed two experimental conditions: Rhodiola rosea supplementation and placebo, administered in a randomized order with a 5-day washout period between conditions.

During the Rhodiola rosea condition, participants received 1,500 mg per day for three consecutive days, followed by an additional 500 mg dose 30 minutes before exercise testing. The placebo condition followed an identical administration schedule without the active supplement.

Following each supplementation condition, participants performed a 30-second Wingate Anaerobic Test to assess anaerobic performance. Blood lactate concentrations were measured before exercise and at 3, 10, and 20 minutes after exercise.

The study was designed to determine whether short-term Rhodiola rosea supplementation influences maximal anaerobic performance and blood lactate concentrations during recovery from high-intensity exercise.

調査の概要

詳細な説明

Rhodiola rosea is a plant-derived supplement containing bioactive compounds, including rosavins and salidroside, that have been investigated for their potential effects on physical performance, fatigue, and exercise-related physiological responses. Although previous research has examined the effects of Rhodiola rosea on different exercise modalities, evidence regarding its influence on anaerobic performance and serial blood lactate responses following a single bout of high-intensity exercise remains limited.

This study investigated whether short-term Rhodiola rosea supplementation affects performance during a 30-second Wingate Anaerobic Test (WAnT-30) and blood lactate concentrations during subsequent recovery.

The study employed a randomized, double-blind, placebo-controlled crossover design. Twenty-three trained male athletes completed both supplementation conditions in a randomized sequence. Participants received either Rhodiola rosea or placebo during the first experimental period and the alternate condition during the second period. A 5-day supplement-free washout interval separated the two supplementation periods.

The Rhodiola rosea supplementation protocol consisted of 1,500 mg daily for three consecutive days, administered in three separate 500 mg doses, followed by an additional 500 mg dose 30 minutes before the exercise test. The placebo consisted of an identically flavored non-caloric beverage without active supplementation. Both preparations were administered under standardized conditions to maintain blinding.

Following each supplementation period, participants completed a standardized warm-up and performed a maximal 30-second Wingate test using a cycle ergometer. Anaerobic performance variables included peak power, relative peak power, mean power, total work, cadence at peak power, and rate of fatigue.

Capillary blood lactate concentrations were assessed at rest and at 3, 10, and 20 minutes following the Wingate test. Participants remained seated throughout the post-exercise recovery period.

Dietary intake, physical activity, caffeine consumption, and testing conditions were standardized as far as possible to minimize potential confounding effects.

The study was designed to evaluate the effects of short-term Rhodiola rosea supplementation on maximal anaerobic performance and post-exercise blood lactate responses compared with placebo.

研究の種類

介入

入学 (実際)

23

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Karaman
      • Karaman、Karaman、トルコ(Türkiye)、70200
        • Faculty of Sports Sciences Exercise Physiology Laboratory

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~24年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

男

説明

Inclusion Criteria:

  • Healthy male athletes aged 18 years or older.
  • Regular participation in sport-specific training at least three times per week.
  • Active participation in organized competitive sports.
  • Engagement in structured training aimed at improving athletic performance.
  • Regular participation in lower-body resistance training as part of habitual training programs.
  • Previous experience with submaximal exercise testing on a cycle ergometer.
  • No musculoskeletal injuries or medical conditions that could affect exercise performance.
  • Maintenance of regular training during the month preceding the study.
  • Voluntary participation and provision of written informed consent.

Exclusion Criteria:

  • Previous use of Rhodiola rosea supplementation.
  • Use of any ergogenic supplements within one week before the beginning of the study or during the experimental period.
  • History of lower-limb surgery within the previous 12 months.
  • Presence of musculoskeletal injuries or medical conditions that could interfere with exercise performance.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Rhodiola rosea Followed by Placebo

Subjects assigned to this sequence received Rhodiola rosea supplementation during the first experimental period, followed by placebo during the second period. Rhodiola rosea was administered at 1,500 mg/day for three consecutive days, with an additional 500 mg dose 30 minutes before the Wingate test. A 5-day supplement-free washout period separated the two experimental periods. Twelve subjects completed this sequence.

Rhodiola rosea extract (Solgar Rhodiola Root Extract, Solgar Inc., USA), standardized to 3% rosavins and 1% salidroside, was administered at 1,500 mg/day for three consecutive days (500 mg three times daily), followed by an additional 500 mg dose 30 minutes before the Wingate Anaerobic Test. The total dose was 5,000 mg per experimental period. The supplement was administered in a non-caloric mango-flavored beverage.

The placebo consisted of an identical non-caloric mango-flavored beverage without Rhodiola rosea extract or any other active supplement. It was administered according to the same schedule as the active supplementation condition to maintain blinding.

実験的:Placebo Followed by Rhodiola rosea

Subjects assigned to this sequence received placebo during the first experimental period, followed by Rhodiola rosea supplementation during the second period. The placebo followed the same administration schedule as the active supplementation condition but contained no Rhodiola rosea extract. A 5-day supplement-free washout period separated the two experimental periods. Eleven subjects completed this sequence.

Rhodiola rosea extract (Solgar Rhodiola Root Extract, Solgar Inc., USA), standardized to 3% rosavins and 1% salidroside, was administered at 1,500 mg/day for three consecutive days (500 mg three times daily), followed by an additional 500 mg dose 30 minutes before the Wingate Anaerobic Test. The total dose was 5,000 mg per experimental period. The supplement was administered in a non-caloric mango-flavored beverage.

The placebo consisted of an identical non-caloric mango-flavored beverage without Rhodiola rosea extract or any other active supplement. It was administered according to the same schedule as the active supplementation condition to maintain blinding.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Peak Power During the 30-Second Wingate Anaerobic Test
時間枠:During the 30-second Wingate test at the end of each 4-day supplementation period

Peak power (W) was measured during the 30-second Wingate Anaerobic Test using a cycle ergometer (Lode Excalibur Sport). The highest power output achieved during the test was recorded and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Post-Exercise Blood Lactate Concentration
時間枠:At rest before exercise and at 3, 10, and 20 minutes post-exercise, following each supplementation period

Capillary blood lactate concentration (mmol/L) was measured using a portable lactate analyzer (Lactate Scout Sport) at rest and at 3, 10, and 20 minutes after the 30-second Wingate Anaerobic Test. Blood lactate concentrations were compared between the Rhodiola rosea and placebo conditions at each measurement time point.

At rest before exercise and at 3, 10, and 20 minutes post-exercise, following each supplementation period

二次結果の測定

結果測定
メジャーの説明
時間枠
Relative Peak Power During the 30-Second Wingate Anaerobic Test
時間枠:During the 30-second Wingate test at the end of each 4-day supplementation period

Relative peak power (W/kg) was calculated by normalizing the highest power output achieved during the 30-second Wingate Anaerobic Test to the subject's body mass. Values were compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Mean Power During the 30-Second Wingate Anaerobic Test
時間枠:During the 30-second Wingate test at the end of each 4-day supplementation period

Mean power (W) was determined as the average mechanical power output generated throughout the 30-second Wingate Anaerobic Test. Values were obtained from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Total Work During the 30-Second Wingate Anaerobic Test
時間枠:During the 30-second Wingate test at the end of each 4-day supplementation period

Total work (kJ) was determined as the cumulative mechanical work performed throughout the 30-second Wingate Anaerobic Test. Values were derived from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Cadence at Peak Power During the 30-Second Wingate Anaerobic Test
時間枠:During the 30-second Wingate test at the end of each 4-day supplementation period

Cadence at peak power (rpm) was recorded as the pedaling rate corresponding to the highest power output achieved during the 30-second Wingate Anaerobic Test. Values were obtained from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Rate of Fatigue During the 30-Second Wingate Anaerobic Test
時間枠:During the 30-second Wingate test at the end of each 4-day supplementation period

Rate of fatigue (%) was obtained from the cycle ergometer software as an indicator of the relative decline in power output during the 30-second Wingate Anaerobic Test. Values were compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Yücel Makaracı, PhD、Karamanoğlu Mehmetbey University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月1日

一次修了 (実際)

2026年5月15日

研究の完了 (実際)

2026年5月15日

試験登録日

最初に提出

2026年11月9日

QC基準を満たした最初の提出物

2026年11月9日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • KMU-09-2025/153
  • 15-YL-25 (その他の助成金/資金番号:Karamanoğlu Mehmetbey University (KMU) Scientific 645 Research Projects (BAP) Unit)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data may be made available from the corresponding author upon reasonable request. Data will not be publicly accessible due to participant privacy considerations. Each request will be evaluated individually based on its scientific purpose, ethical considerations, and applicable data protection requirements. Data sharing will be subject to appropriate safeguards to protect participant confidentiality.

IPD 共有時間枠

Following publication of the study results, upon reasonable request.

IPD 共有アクセス基準

Qualified researchers may request access to de-identified individual participant data by contacting the corresponding author. Each request will be evaluated individually based on its scientific purpose, methodological justification, and compliance with applicable ethical and data protection requirements. Data may be shared upon reasonable request, provided that participant confidentiality and privacy are adequately protected.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する